Amgen to Buy Celgene’s Otezla for $13.4 Billion

Written by Bryan Shin

et|icon_calendar|

August 27, 2019

et|icon_grid-3×3|

The American multinational biopharmaceutical company, Amgen (NASDAQ: AMGN) agreed to buy Celgene’s (NASDAQ: CELG) Otezla, which is a psoriasis treatment, for USD 13.4 Billion.

The acquisition clears the way for Bristol-Myers Squibb to push ahead with its USD 90 Billion takeover of Celgene announced in early January. Otezla had sales of USD 1.61 Billion last year and the sales are expected to grow at least in the low-double digits over the next five years.

The focus of most of pharmaceutical groups is on becoming part of the top three players in the industry. Indeed, as Pharmaceutical and Healthcare companies own drugs are close to losing patent protection, the majority of the deals in the industry this year have been mostly driven by the will to sell non-core assets or buy innovative medicines according to the Financial Times.

So far this year, more than USD 700 Billion worth of transactions have been agreed in the pharmaceutical and healthcare sector, but Bristol-Myers’s acquisition of Celgene is the largest in the largest pharma deal.

The deal is expected to produce tax benefits of a USD 2.2 Billion present cash value for Amgen and Bristol-Myers said most of the profits from the sale will be used to pay back debt from the Celgene deal and has announced that it plans to buy back USD 7 Billion worth of shares, up from the previously planned USD 5 Billion.

Stock price

DAY LOW/HIGH

52 week low/high

Comparables

Related Articles

U.S. Judge Approves CVS-Aetna Merger

U.S. Judge Approves CVS-Aetna Merger

U.S. Judge Approves CVS-Aetna Merger0 Comments A federal judge on Wednesday formally approved the merger of CVS Health (NYSE: CVS) and U.S. health insurer Aetna, Inc. Judge Richard Leon of the U.S. District Court for the District of Columbia...

Pfizer to Merge Subsidiary with Mylan

Pfizer to Merge Subsidiary with Mylan

Pfizer to Merge Subsidiary with Mylan0 Comments Pfizer (NYSE: PFE) announced on Monday morning that its subsidiary, Upjohn will merge with Mylan (NASDAQ: MYL). Following the news, Mylan shares rose by 13% during Monday’s pre-market hours. Under...

CVS Shares Rise Amid Market Tumble

CVS Shares Rise Amid Market Tumble

CVS Shares Rise Amid Market Tumble0 Comments Despite the market tumbling lower on Wednesday, CVS Health Corporation (NYSE: CVS) reportedearnings that propelled the stock 5% higher in early morning trading. CVS raised its guidance for its...

Comments

Leave a Reply

avatar
  Subscribe  
Notify of